Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
HIV Clinical Trials|April 27, 2002
Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responsesFranco Lori, Andrea Foli, Renato Maserati, et al.
Analytical Chemistry|January 25, 2019
ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic AmyloidosisDiletta Ami, Paolo Mereghetti, Andrea Foli, et al.
Blood|June 30, 2022
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survivalMarco Basset, Paolo Milani, Andrea Foli, et al.
AIDS (London, England)|January 26, 2005
Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytesLuca Lova, Antonella Groff, Elisabetta Ravot, et al.
Blood|May 20, 2015
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosisGiovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2008
HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individualsSandra A Calarota, Andrea Foli, Renato Maserati, et al.
Current HIV Research|May 17, 2007
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAARTRenato Maserati, Andrea Foli, Lina Tomasoni, et al.
Leukemia & Lymphoma|August 27, 2021
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosisGiovanni Palladini, Simone Celant, Paolo Milani, et al.
The FEBS Journal|September 5, 2021
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregationGiulia Mazzini, Stefano Ricagno, Serena Caminito, et al.
Annals of Hematology|August 10, 2011
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosisRiccardo Caccialanza, Giovanni Palladini, Catherine Klersy, et al.
Pageof 7